Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic Cancer

March 16, 2020
FGCL-3019-087
Pancreatic Cancer
Alexander Hantel, MD

Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield

 This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with gemcitabine plus nab-paclitaxel (G/NP) in the treatment of locally advanced, unresectable pancreatic cancer subjects.

Sponsor:FibroGen

https://clinicaltrials.gov/ct2/show/NCT03941093

  • Locally advanced pancreatic ductal adenocarcinoma (PDAC) considered unresectable
  • No prior chemotherapy or radiation for pancreatic cancer
  • No malignancy diagnosis within the previous 3 years except non-melanoma skin cancer and in situ carcinomas (excluding in situ breast cancer)
  • No medical or surgical condition that may place the subject at increased risk while on study
  • No uncontrolled illness including, but not limited to, ongoing or active systemic infections, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • No documented history of drug or alcohol abuse within 6 months of signing informed consent
Lifetime
Accepting Participants
Interventional
III
Kathy Seymour, BSN
630-646-6075
630-646-6110
630-646-63072